247 related articles for article (PubMed ID: 23908446)
1. Safety and effectiveness of 6 months' etanercept monotherapy and combination therapy in Japanese patients with rheumatoid arthritis: effect of concomitant disease-modifying antirheumatic drugs.
Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Tanaka Y; Yamanaka H; Hirose T; Yoshinaga T; Suzukawa M
J Rheumatol; 2013 Oct; 40(10):1658-68. PubMed ID: 23908446
[TBL] [Abstract][Full Text] [Related]
2. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study.
van Riel PL; Taggart AJ; Sany J; Gaubitz M; Nab HW; Pedersen R; Freundlich B; MacPeek D;
Ann Rheum Dis; 2006 Nov; 65(11):1478-83. PubMed ID: 16464988
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial.
Kim HY; Hsu PN; Barba M; Sulaiman W; Robertson D; Vlahos B; Khandker R; Nab H; Freundlich B; Koenig A
Int J Rheum Dis; 2012 Apr; 15(2):188-96. PubMed ID: 22462423
[TBL] [Abstract][Full Text] [Related]
5. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis.
Bae SC; Gun SC; Mok CC; Khandker R; Nab HW; Koenig AS; Vlahos B; Pedersen R; Singh A
BMC Musculoskelet Disord; 2013 Jan; 14():13. PubMed ID: 23294908
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
[TBL] [Abstract][Full Text] [Related]
7. Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate.
Koyama Y; Shiraishi H; Ohta T; Uchino A
Mod Rheumatol; 2012 Feb; 22(1):100-8. PubMed ID: 21706263
[TBL] [Abstract][Full Text] [Related]
8. Etanercept for the treatment of rheumatoid arthritis.
Lethaby A; Lopez-Olivo MA; Maxwell L; Burls A; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2013 May; 2013(5):CD004525. PubMed ID: 23728649
[TBL] [Abstract][Full Text] [Related]
9. A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis.
Takeuchi T; Miyasaka N; Zang C; Alvarez D; Fletcher T; Wajdula J; Yuasa H; Vlahos B
Mod Rheumatol; 2013 Jul; 23(4):623-33. PubMed ID: 23011358
[TBL] [Abstract][Full Text] [Related]
10. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial.
Nam JL; Villeneuve E; Hensor EM; Wakefield RJ; Conaghan PG; Green MJ; Gough A; Quinn M; Reece R; Cox SR; Buch MH; van der Heijde DM; Emery P
Ann Rheum Dis; 2014 Jun; 73(6):1027-36. PubMed ID: 24618266
[TBL] [Abstract][Full Text] [Related]
11. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis.
Pope JE; Haraoui B; Thorne JC; Vieira A; Poulin-Costello M; Keystone EC
Ann Rheum Dis; 2014 Dec; 73(12):2144-51. PubMed ID: 23979914
[TBL] [Abstract][Full Text] [Related]
12. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial.
Kameda H; Ueki Y; Saito K; Nagaoka S; Hidaka T; Atsumi T; Tsukano M; Kasama T; Shiozawa S; Tanaka Y; Takeuchi T;
Mod Rheumatol; 2010 Dec; 20(6):531-8. PubMed ID: 20574649
[TBL] [Abstract][Full Text] [Related]
13. Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study.
Gaubitz M; Göttl KH; Behmer O; Lippe R; Meng T; Löschmann PA
Clin Rheumatol; 2017 Sep; 36(9):1989-1996. PubMed ID: 28756532
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Symmons DP; Watson KD; Silman AJ;
Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
[TBL] [Abstract][Full Text] [Related]
15. Longterm retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapy.
Matsubara H; Kojima T; Kaneko A; Hirano Y; Ishikawa H; Hattori Y; Miyake H; Oguchi T; Takagi H; Yabe Y; Kato T; Ito T; Fukaya N; Kanayama Y; Shioura T; Hayashi M; Fujibayashi T; Takahashi N; Funahashi K; Kato D; Hanabayashi M; Terabe K; Ishiguro N
J Rheumatol; 2014 Aug; 41(8):1583-9. PubMed ID: 25028370
[TBL] [Abstract][Full Text] [Related]
16. Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate.
Tkacz J; Gharaibeh M; DeYoung KH; Wilson K; Collier D; Oko-Osi H
J Manag Care Spec Pharm; 2020 Mar; 26(3):285-294. PubMed ID: 32105179
[TBL] [Abstract][Full Text] [Related]
17. Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).
Gibofsky A; Cannon GW; Harrison DJ; Joseph GJ; Bitman B; Chaudhari S; Collier DH
Clin Exp Rheumatol; 2015; 33(3):297-301. PubMed ID: 25738333
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis.
Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Tanaka Y; Yamanaka H; Fujii K; Yoshinaga T; Freundlich B; Suzukawa M
Rheumatol Int; 2012 Jun; 32(6):1511-9. PubMed ID: 21327436
[TBL] [Abstract][Full Text] [Related]
19. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
Moreland LW; O'Dell JR; Paulus HE; Curtis JR; Bathon JM; St Clair EW; Bridges SL; Zhang J; McVie T; Howard G; van der Heijde D; Cofield SS;
Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
[TBL] [Abstract][Full Text] [Related]
20. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]